share_log

科伦药业:关于子公司核心产品芦康沙妥珠单抗(sac-TMT)于2024年美国癌症研究协会年会上刊发研究成果的公告

Colon Pharmaceuticals: Announcement on the publication of research results on the subsidiary's core product, lukansastuzumab (Sac-TMT), at the 2024 American Association for Cancer Research Annual Meeting

Sensex a share ·  Apr 7
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more